Table: Sumitomo Pharma -Q1 group results (IFRS)

Sumitomo Pharma

31/07/2024 07:30

Jul 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 3 months ended      3 months ended        Year to  
                Jun 30, 2024        Jun 30, 2023      Mar 31, 2025  
                   LATEST             YEAR-AGO           COMPANY    
                   RESULTS             RESULT           FORECAST    
  Sales             90.68               75.69            338.00     
                 (+19.8 pct)         (-52.7 pct)       (+7.5 pct)   
  Operating       loss 3.11          loss 51.57           0 mln     
  Pretax
  Net               15.94            loss 38.87        loss 16.00   
  EPS Basic       40.11 yen        loss 97.82 yen    loss 40.27 yen 
  Ann Div                                NIL               NIL      
  -Q2 Div                                NIL               NIL      
  -Q4 Div                                NIL               NIL      
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T